Episode 248: Am I Going to Go Blind on a GLP-1? Understanding the NAION Headlines

If you've seen headlines linking Ozempic and other GLP-1 medications to sudden eye strokes, I want to stop the panic right here.

In this episode, I break down what the research on NAION actually shows, who's really at risk, and why the scary relative-risk numbers you're seeing online don't tell the whole story.

I walk you through what NAION is, why patients on semaglutide often already carry the underlying risk factors that get left out of the clickbait, and what the difference is between an observational study raising a signal and a randomized trial proving cause and effect. I also share the warning signs that mean you should go to the ER immediately, not wait for your next appointment.

You'll walk away knowing exactly how to think about this headline, what questions to bring to your own doctor, and why staying on your medication is usually the right call.

Episode Highlights:

What NAION is and how it affects the optic nerve

The risk factors patients on GLP-1s often already have

What the 37-million-person study actually found — and didn't

Why randomized trials tell a different story than observational data

Absolute risk vs. relative risk, explained simply

Warning signs that mean go to the ER now

Why sleep apnea complicates the whole picture